Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom DuBois who wrote (2455)	10/22/1997 8:11:00 PM
From: JOHN W.	Read Replies (1) of 6136

The 6-9 months was from L.Moss. "70 by Nov" was irrespective of European approval. Roche will initiate the "launch" prior to Christmas. My guess is that another short lived runup will occur prior to approval and sell off soon thereafter, like back in March. The major move to 70+ is based on the pattern of AGPH that had developed and the rumors/heresay I have heard regarding the data that will be released on AG2034 and AG3340 by Nov (several analyst also mention in upcoming milestones the AG2034 data in 2H:97). Examining how the stock traded at the end of today, I think we have established a firm support level in the low 50s. With an overall stable mkt, it will be very interesting to see if "capitulation" occurs Thursday/Friday. The IGEN deal is a commitment to rapidity of delivering the pipeline ( cure for the common cold) to mkt, although having developed the best protease inhibitor in 38 months is incredible. Alanex/IGEN=speed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next